Prognostic significance of survivin polymorphisms on non-small cell lung cancer survival

Journal of Thoracic Oncology

Volumn 5, Issue 11, 2010, Pages 1748-1754

  Dai, Juncheng ^a   Jin, Guangfu ^a   Dong, Jing ^a   Chen, Yijiang ^a   Xu, Lin ^b   Hu, Zhibin ^a   Shen, Hongbing ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b JIANGSU CANCER HOSPITAL   (China)

Author keywords

NSCLC; Polymorphism; Prognosis; Survivin

Indexed keywords

PLATINUM; SURVIVIN;

ADULT; AGE; ALLELE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CHINESE; COHORT ANALYSIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; DNA MODIFICATION; FEMALE; FOLLOW UP; GENDER; GENOTYPE; HAZARD RATIO; HIGH RISK POPULATION; HISTOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

EID: 78149469510     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181f18cb9     Document Type: Article

References (45)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Altieri DC, Marchisio PC. Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest 1999;79:1327-1333.
3. Deveraux QL, Takahashi R, Salvesen GS, et al. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997;388:300-304.
4. Uren AG, Coulson EJ, Vaux DL. Conservation of baculovirus inhibitor of apoptosis repeat proteins (BIRPs) in viruses, nematodes, vertebrates and yeasts. Trends Biochem Sci 1998;23:159-162.
5. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-921.
6. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003;22:8581-8589.
7. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003;3:46-54.
8. Blanc-Brude OP, Mesri M, Wall NR, et al. Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res 2003;9: 2683-2692.
9. Chiou SK, Jones MK, Tarnawski AS. Survivin-an anti-apoptosis protein: its biological roles and implications for cancer and beyond. Med Sci Monit 2003;9:PI25-PI29.
10. Monzo M, Rosell R, Felip E, et al. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 1999;17:2100-2104.
11. Xu Y, Fang F, Ludewig G, et al. A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol 2004;23:527-537.
12. Borbely AA, Murvai M, Szarka K, et al. Survivin promoter polymorphism and cervical carcinogenesis. J Clin Pathol 2007;60:303-306.
13. Cheng ZJ, Hu LH, Huang SJ. Correlation of -31G/C polymorphisms of survivin promoter to tumorigenesis of gastric carcinoma. Ai Zheng 2008;27:258-263.
14. Jang JS, Kim KM, Kang KH, et al. Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer 2008;60:31-39.
15. Yang L, Zhu H, Zhou B, et al. The association between the survivin C-31G polymorphism and gastric cancer risk in a Chinese population. Dig Dis Sci 2009;54:1021-1028.
16. Zhang M, Hu Z, Huang J, et al. A 3′-untranslated region polymorphism in IGF1 predicts survival of non-small cell lung cancer in a Chinese population. Clin Cancer Res 2010;16:1236-1244.
17. Hu Z, Wang H, Shao M, et al. Genetic variants in MGMT and risk of lung cancer in Southeastern Chinese: a haplotype-based analysis. Hum Mutat 2007;28:431-440.
18. Chakravarti A, Noll E, Black PM, et al. Quantitatively determinedsurvivin expression levels are of prognostic value in human gliomas. J Clin Oncol 2002;20:1063-1068.
19. Kappler M, Bache M, Bartel F, et al. Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53. Cancer Gene Ther 2004;11: 186-193.
20. Kawasaki H, Altieri DC, Lu CD, et al. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998;58:5071-5074.
21. Satoh K, Kaneko K, Hirota M, et al. Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer. Pancreas 2001;23:251-258.
22. Tanaka K, Iwamoto S, Gon G, et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000;6:127-134.
23. Floyd HS, Jennings-Gee JE, Kock ND, et al. Genetic and epigenetic alterations in lung tumors from bitransgenic Ki-rasG12C expressing mice. Mol Carcinog 2006;45:506-517.
24. Gazouli M, Tzanakis N, Rallis G, et al. Survivin -31G/C promoter polymorphism and sporadic colorectal cancer. Int J Colorectal Dis 2009;24:145-150.
25. Han CH, Wei Q, Lu KK, et al. Polymorphisms in the survivin promoter are associated with age of onset of ovarian cancer. Int J Clin Exp Med 2009;2:289-299.
26. Nakano J, Huang CL, Liu D, et al. Survivin gene expression is negatively regulated by the p53 tumor suppressor gene in non-small cell lung cancer. Int J Oncol 2005;27:1215-1221.
27. Saitoh Y, Yaginuma Y, Ishikawa M. Analysis of Bcl-2, Bax and Survivin genes in uterine cancer. Int J Oncol 1999;15:137-141.
28. Teodoridis JM, Hall J, Marsh S, et al. CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 2005; 65:8961-8967.
29. Vegran F, Boidot R, Oudin C, et al. Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer. Oncogene 2007;26:290-297.
30. Wagner M, Schmelz K, Dorken B, et al. Epigenetic and genetic analysis of the survivin promoter in acute myeloid leukemia. Leuk Res 2008;32: 1054-1060.
31. Yang X, Xiong G, Chen X, et al. Polymorphisms of survivin promoter are associated with risk of esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2009;135:1341-1349.
32. Karna P, Sharp SM, Yates C, et al. EM011 activates a surviving-dependent apoptotic program in human non-small cell lung cancer cells. Mol Cancer 2009;8:93.
33. Krepela E, Dankova P, Moravcikova E, et al. Increased expression of inhibitor of apoptosis proteins, survivin and XIAP, in non-small cell lung carcinoma. Int J Oncol 2009;35:1449-1462.
34. Chen P, Li J, Ge LP, et al. Prognostic value of survivin, X-linked inhibitor of apoptosis protein and second mitochondria-derived activator of caspases expression in advanced non-small-cell lung cancer patients. Respirology 2010;15:501-509.
35. Fan J, Wang L, Jiang GN, et al. The role of survivin on overall survival of non-small cell lung cancer, a meta-analysis of published literatures. Lung Cancer 2008;61:91-96.
36. Li F, Altieri DC. Transcriptional analysis of human survivin gene expression. Biochem J 1999;344(Pt 2):305-311.
37. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998;396:580-584.
38. Adida C, Berrebi D, Peuchmaur M, et al. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 1998;351:882-883.
39. Dohi T, Okada K, Xia F, et al. An IAP-IAP complex inhibits apoptosis. J Biol Chem 2004;279:34087-34090.
40. Reed JC. The Survivin saga goes in vivo. J Clin Invest 2001;108:965-969.
41. Schlette EJ, Medeiros LJ, Goy A, et al. Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol 2004; 22:1682-1688.
42. Zaffaroni N, Daidone MG. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist Updat 2002;5:65-72.
43. Biran A, Brownstein M, Haklai R, et al. Downregulation of survivin and aurora a by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy. Int J Cancer 2010 Apr 5. [Epub ahead of print].
44. Kanwar RK, Cheung CH, Chang JY, et al. Recent advances in antisurvivin treatments for cancer. Curr Med Chem 2010;17:1509-1515.
45. Ryan BM, O'Donovan N, Duffy MJ. Survivin: a new target for anticancer therapy. Cancer Treat Rev 2009;35:553-562.